Friday, 10 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > Vertex non-opioid pain drug Journavx appoved by FDA
Health and Wellness

Vertex non-opioid pain drug Journavx appoved by FDA

Last updated: January 31, 2025 1:15 am
Share
SHARE

Vertex Pharmaceuticals has recently received approval from the Food and Drug Administration for their new non-opioid pain drug, Journavx. This approval marks a significant milestone for the company and paves the way for the launch of a product that has garnered both high hopes and mixed opinions among physicians and market analysts.

Journavx is designed for the twice-daily treatment of moderate to severe acute pain, such as the kind of sharp, short-lived aches that may follow a bike accident or a surgical procedure. The FDA’s decision to approve the drug was based on the results of two late-stage trials, which showed that patients undergoing procedures like tummy tucks or bunion surgery experienced significantly less pain after taking Journavx compared to those who received a placebo. Additionally, the trials demonstrated that the drug was generally safe, with fewer adverse events reported in the Journavx group compared to the placebo group.

Priced at $31 per day, Journavx is expected to generate $1.5 billion in annual revenue by 2030, according to market analysts. This estimate does not include potential sales for chronic pain, where there is a larger market opportunity that Vertex is also exploring through ongoing clinical trials.

The approval of Journavx represents a significant advancement in the field of pain management, offering patients a non-opioid alternative for managing acute pain. With its promising efficacy and safety profile, Journavx has the potential to address unmet needs in pain management and improve the quality of life for patients experiencing acute pain.

As Vertex Pharmaceuticals prepares to launch Journavx in the market, the company is poised to make a significant impact in the healthcare industry and provide patients with a much-needed alternative to traditional pain medications. With its innovative approach to pain management, Journavx has the potential to revolutionize the way acute pain is treated and pave the way for future advancements in the field.

See also  Drug overdose deaths dropped 27% in 2024, CDC reports| STAT
TAGGED:appovedDrugFDAJournavxnonopioidpainVertex
Share This Article
Twitter Email Copy Link Print
Previous Article De’Aaron Fox laughs off Kings fan’s call out for getting Tyrese Haliburton traded and Mike Brown fired before imminent trade 
Next Article Lions’ Amik Robertson Says Jets In ‘Good Hands’ W/ Aaron Glenn, Predicts ‘Great Things’
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

The Defensive Line And Suicide Prevention For Underserved Communities

hands holding yellow ribbon for suicide prevention getty Earlier this month, a significant article on…

September 29, 2025

Three Ways The Traitors Season 3 Train Leavers Could Return

Overall, the return of Fozia, Jack, and Alexander on The Traitors has sparked much speculation…

January 2, 2025

The Case for a Faculty Union at the School of Visual Arts

Art schools play a crucial role in shaping the future of education and the creative…

April 30, 2025

Fed Governor Bowman says December interest rate cut should be the last

Federal Reserve Governor Michelle Bowman recently expressed her support for the recent interest rate cuts…

January 9, 2025

The Future Of Healthcare Is Collaborative—And AI Is The Catalyst

The healthcare landscape in India is undergoing a significant transformation, driven by the collaboration between…

June 11, 2025

You Might Also Like

STAT+: HHS employees to be fired as White House enacts mass terminations it blames on shutdown
Health and Wellness

STAT+: HHS employees to be fired as White House enacts mass terminations it blames on shutdown

October 10, 2025
No, circumcision doesn’t cause autism
Health and Wellness

No, circumcision doesn’t cause autism

October 10, 2025
Jay Shetty and his health advice are everywhere. It’s by design
Health and Wellness

Jay Shetty and his health advice are everywhere. It’s by design

October 10, 2025
Cancer drug maker takes sudden pivot into crypto
Economy

Cancer drug maker takes sudden pivot into crypto

October 9, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?